{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:45:25Z","timestamp":1789037125523,"version":"build-2803163510"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Postdoctor Research Fund of West China Hospital, Sichuan University","award":["No. 2024HXBH084"],"award-info":[{"award-number":["No. 2024HXBH084"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82572070"],"award-info":[{"award-number":["No. 82572070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sichuan Province Science and Technology Department","award":["No. 2024YFFK0349, 2025ZNSFSC0638, 2024YFFK0062"],"award-info":[{"award-number":["No. 2024YFFK0349, 2025ZNSFSC0638, 2024YFFK0062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09151-9","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:25:01Z","timestamp":1776684301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Evolving Landscape of CAR T-Cell Therapy in Autoimmune Diseases: A State-of-the-Art Review (2025)"],"prefix":"10.1007","volume":"69","author":[{"given":"Changpei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"9151_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223\u2013243. https:\/\/doi.org\/10.1006\/clin.1997.4412","journal-title":"Clin Immunol Immunopathol"},{"key":"9151_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","volume":"29","author":"WW Eaton","year":"2007","unstructured":"Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29:1\u20139. https:\/\/doi.org\/10.1016\/j.jaut.2007.05.002","journal-title":"J Autoimmun"},{"key":"9151_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278:369\u2013395. https:\/\/doi.org\/10.1111\/joim.12395","journal-title":"J Intern Med"},{"key":"9151_CR4","doi-asserted-by":"publisher","first-page":"e39302","DOI":"10.1016\/j.heliyon.2024.e39302","volume":"10","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wang X, Hu Z, Huang R, Yang G, Wang R et al (2024) Advances in hematopoietic stem cell transplantation for autoimmune diseases. Heliyon 10:e39302. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39302","journal-title":"Heliyon"},{"key":"9151_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-025-00507-3","author":"H Ledford","year":"2025","unstructured":"Ledford H (2025) Woman in cancer remission for record 19 years after CAR-T immune treatment. Nature. https:\/\/doi.org\/10.1038\/d41586-025-00507-3","journal-title":"Nature"},{"key":"9151_CR6","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","volume":"84","author":"MR Roberts","year":"1994","unstructured":"Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ et al (1994) Targeting of human immunodeficiency virus-infected cells by CD8\u2009+\u2009T lymphocytes armed with universal T-cell receptors. Blood 84:2878\u20132889","journal-title":"Blood"},{"key":"9151_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini CR, Ellis GI, Riley JL (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18 :605 \u2013 16. https:\/\/doi.org\/10.1038\/s41577-018-0042-2","journal-title":"Nat Rev Immunol"},{"key":"9151_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.1500751","volume":"195","author":"DM Barrett","year":"2015","unstructured":"Barrett DM, Grupp SA, June CH (2015) Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. J Immunol 195:755\u2013761. https:\/\/doi.org\/10.4049\/jimmunol.1500751","journal-title":"J Immunol"},{"key":"9151_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"key":"9151_CR10","doi-asserted-by":"publisher","unstructured":"Lee A (2025) Obecabtagene Autoleucel: First Approval Mol Diagn Ther. https:\/\/doi.org\/10.1007\/s40291-025-00771-z","DOI":"10.1007\/s40291-025-00771-z"},{"key":"9151_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T et al (2025) The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transpl 60:519\u2013528. https:\/\/doi.org\/10.1038\/s41409-025-02524-2","journal-title":"Bone Marrow Transpl"},{"key":"9151_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS et al (2015) CAR-T Cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res 3:483\u2013494. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0048","journal-title":"Cancer Immunol Res"},{"key":"9151_CR13","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.4049\/jimmunol.164.7.3705","volume":"164","author":"PK Darcy","year":"2000","unstructured":"Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM et al (2000) Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 164:3705\u20133712. https:\/\/doi.org\/10.4049\/jimmunol.164.7.3705","journal-title":"J Immunol"},{"key":"9151_CR14","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.4049\/jimmunol.169.10.5780","volume":"169","author":"NM Haynes","year":"2002","unstructured":"Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al (2002) Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 169:5780\u20135786. https:\/\/doi.org\/10.4049\/jimmunol.169.10.5780","journal-title":"J Immunol"},{"key":"9151_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/2326-6066.Cir-18-0065","volume":"6","author":"LK Hong","year":"2018","unstructured":"Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G et al (2018) CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30(+) and CD30(-) Embryonal Carcinoma via Antigen-Dependent and Fas\/FasL Interactions. Cancer Immunol Res 6:1274\u20131287. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0065","journal-title":"Cancer Immunol Res"},{"key":"9151_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720\u2013724. https:\/\/doi.org\/10.1073\/pnas.90.2.720","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9151_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol 20:70\u201375. https:\/\/doi.org\/10.1038\/nbt0102-70","journal-title":"Nat Biotechnol"},{"key":"9151_CR18","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:10024\u201310028. https:\/\/doi.org\/10.1073\/pnas.86.24.10024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9151_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676\u2013684. https:\/\/doi.org\/10.1038\/sj.leu.2403302","journal-title":"Leukemia"},{"key":"9151_CR20","doi-asserted-by":"publisher","unstructured":"Guedan S, Posey AD Jr., Shaw C, Wing A, Da T, Patel PR et al (2018) Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3 https:\/\/doi.org\/10.1172\/jci.insight.96976","DOI":"10.1172\/jci.insight.96976"},{"key":"9151_CR21","doi-asserted-by":"publisher","first-page":"839783","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H et al (2022) GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18. Front Immunol 13:839783. https:\/\/doi.org\/10.3389\/fimmu.2022.839783","journal-title":"Front Immunol"},{"key":"9151_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K et al (2018) A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24:352\u2013359. https:\/\/doi.org\/10.1038\/nm.4478","journal-title":"Nat Med"},{"key":"9151_CR23","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359\u20137368. https:\/\/doi.org\/10.1038\/sj.onc.1206939","journal-title":"Oncogene"},{"key":"9151_CR24","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","volume":"118","author":"S Audia","year":"2011","unstructured":"Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M et al (2011) Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 118:4394\u20134400. https:\/\/doi.org\/10.1182\/blood-2011-03-344051","journal-title":"Blood"},{"key":"9151_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67:917\u2013925. https:\/\/doi.org\/10.1136\/ard.2007.080960","journal-title":"Ann Rheum Dis"},{"key":"9151_CR26","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","volume":"11","author":"M Rehnberg","year":"2009","unstructured":"Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M (2009) Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 11:R123. https:\/\/doi.org\/10.1186\/ar2789","journal-title":"Arthritis Res Ther"},{"key":"9151_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J et al (2025) CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis 84:106\u2013114. https:\/\/doi.org\/10.1136\/ard-2024-226142","journal-title":"Ann Rheum Dis"},{"key":"9151_CR28","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.jaut.2025.103369","volume":"151","author":"V Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, Feinberg D, Webber BR, Moriarity BS et al (2025) CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun 151:103369. https:\/\/doi.org\/10.1016\/j.jaut.2025.103369","journal-title":"J Autoimmun"},{"key":"9151_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/jimmun\/vkaf008","volume":"214","author":"D Suan","year":"2025","unstructured":"Suan D, Moore J, Goodnow CC (2025) Can autoimmune disease be cured by deep CD19\u2009+\u2009cell depletion? J Immunol 214:1075\u20131092. https:\/\/doi.org\/10.1093\/jimmun\/vkaf008","journal-title":"J Immunol"},{"key":"9151_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01141-w","author":"T Junt","year":"2025","unstructured":"Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G et al (2025) Defining immune reset: achieving sustained remission in autoimmune diseases. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-025-01141-w","journal-title":"Nat Rev Immunol"},{"key":"9151_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01210-9","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM (2025) Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol. https:\/\/doi.org\/10.1038\/s41584-024-01210-9","journal-title":"Nat Rev Rheumatol"},{"key":"9151_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ram\u00edrez-Valle","year":"2024","unstructured":"Ram\u00edrez-Valle F, Maranville JC, Roy S, Plenge RM (2024) Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov 23:501\u2013524. https:\/\/doi.org\/10.1038\/s41573-024-00959-8","journal-title":"Nat Rev Drug Discov"},{"key":"9151_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/nejm199807303390501","volume":"339","author":"C Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339:285\u2013291. https:\/\/doi.org\/10.1056\/nejm199807303390501","journal-title":"N Engl J Med"},{"key":"9151_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3899\/jrheum.180226","volume":"46","author":"H Jethwa","year":"2019","unstructured":"Jethwa H, Lam S, Smith C, Giles I (2019) Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. J Rheumatol 46:245\u2013250. https:\/\/doi.org\/10.3899\/jrheum.180226","journal-title":"J Rheumatol"},{"key":"9151_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.hemonc.2016.05.003","volume":"10","author":"S Siddiqui","year":"2017","unstructured":"Siddiqui S, Bilal M, Otaibi Z, Bilimoria F, Patel N, Rossetti J (2017) Paraneoplastic pemphigus as a presentation of acute myeloid leukemia: Early diagnosis and remission. Hematol Oncol Stem Cell Ther 10:155\u2013160. https:\/\/doi.org\/10.1016\/j.hemonc.2016.05.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"9151_CR36","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/j.bjps.2014.03.014","volume":"67","author":"RT Siau","year":"2014","unstructured":"Siau RT, Morris A, Karoo RO (2014) Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg 67:e162\u2013e164. https:\/\/doi.org\/10.1016\/j.bjps.2014.03.014","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"9151_CR37","doi-asserted-by":"publisher","first-page":"eabq1693","DOI":"10.1126\/scitranslmed.abq1693","volume":"14","author":"J Ruder","year":"2022","unstructured":"Ruder J, Docampo MJ, Rex J, Obahor S, Naghavian R, M\u00fcller AMS et al (2022) Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis. Sci Transl Med 14:eabq1693. https:\/\/doi.org\/10.1126\/scitranslmed.abq1693","journal-title":"Sci Transl Med"},{"key":"9151_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","volume":"2","author":"LCM Arruda","year":"2018","unstructured":"Arruda LCM, Malmegrim KCR, Lima-J\u00fanior JR, Clave E, Dias JBE, Moraes DA et al (2018) Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Adv 2:126\u2013141. https:\/\/doi.org\/10.1182\/bloodadvances.2017011072","journal-title":"Blood Adv"},{"key":"9151_CR39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3389\/fimmu.2018.00834","volume":"9","author":"PJ Darlington","year":"2018","unstructured":"Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME et al (2018) Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. Front Immunol 9:834. https:\/\/doi.org\/10.3389\/fimmu.2018.00834","journal-title":"Front Immunol"},{"key":"9151_CR40","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z et al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv 1:2742\u20132755. https:\/\/doi.org\/10.1182\/bloodadvances.2017010041","journal-title":"Blood Adv"},{"key":"9151_CR41","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"9151_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S et al (2024) CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up. N Engl J Med 390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"9151_CR43","doi-asserted-by":"publisher","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong M-H, Zhou L-Q, Wang W, Cai S-B, You Y-F et al (2024) Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A 121:e2315990121. https:\/\/doi.org\/10.1073\/pnas.2315990121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9151_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","volume":"26","author":"M Claus","year":"2024","unstructured":"Claus M, Freitag M, Ewald M, Rodon L, Deicher F, Watzl C et al (2024) Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study. Arthritis Res Ther 26:211. https:\/\/doi.org\/10.1186\/s13075-024-03451-1","journal-title":"Arthritis Res Ther"},{"key":"9151_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.molimm.2013.11.013","volume":"62","author":"A Sang","year":"2014","unstructured":"SangA, Zheng YY, Morel L (2014) Contributions of B cells to lupus pathogenesis. Mol Immunol 62:329\u2013338. https:\/\/doi.org\/10.1016\/j.molimm.2013.11.013","journal-title":"Mol Immunol"},{"key":"9151_CR46","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M et al (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11:eaav1648. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648","journal-title":"Sci Transl Med"},{"key":"9151_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 385:567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"key":"9151_CR48","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18:1896\u20131903. https:\/\/doi.org\/10.1038\/s41423-020-0472-1","journal-title":"Cell Mol Immunol"},{"key":"9151_CR49","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1056\/NEJMc2114593","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, Schett G (2021) More on CD19-CAR T Cells in Systemic Lupus Erythematosus. Reply New Engl J Med 385:e67. https:\/\/doi.org\/10.1056\/NEJMc2114593","journal-title":"Reply New Engl J Med"},{"key":"9151_CR50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","volume":"180","author":"DJ DiLillo","year":"2008","unstructured":"DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM et al (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180:361\u2013371. https:\/\/doi.org\/10.4049\/jimmunol.180.1.361","journal-title":"J Immunol"},{"key":"9151_CR51","doi-asserted-by":"publisher","first-page":"107487","DOI":"10.1016\/j.isci.2023.107487","volume":"26","author":"JJ Wilson","year":"2023","unstructured":"Wilson JJ, Wei J, Daamen AR, Sears JD, Bechtel E, Mayberry CL et al (2023) Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. iScience 26:107487. https:\/\/doi.org\/10.1016\/j.isci.2023.107487","journal-title":"iScience"},{"key":"9151_CR52","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","volume":"31","author":"D Nunez","year":"2023","unstructured":"Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, M\u00fcller F et al (2023) Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol Therapy Methods Clin Dev 31:101104. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.023","journal-title":"Mol Therapy Methods Clin Dev"},{"key":"9151_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00393-025-01705-0","volume":"84","author":"J Taubmann","year":"2025","unstructured":"Taubmann J, B\u00f6ltz S, Hagen M, Wirsching A, M\u00fcller F, V\u00f6lkl S et al (2025) Langzeitverlauf von Effizienz und Sicherheit der CD19-CAR T-Zell-Therapie beim systemischen Lupus erythematodes. Z Rheumatol 84:612\u2013620. https:\/\/doi.org\/10.1007\/s00393-025-01705-0","journal-title":"Z Rheumatol"},{"key":"9151_CR54","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.eclinm.2025.103229","volume":"83","author":"J Shu","year":"2025","unstructured":"Shu J, Xie W, Mei C, Ren A, Ke S, Ma M et al (2025) Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. eClinicalMedicine 83:103229. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103229","journal-title":"eClinicalMedicine"},{"key":"9151_CR55","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/s0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S et al (2024) CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403:1627\u20131630. https:\/\/doi.org\/10.1016\/s0140-6736(24)00424-0","journal-title":"Lancet"},{"key":"9151_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","volume":"35","author":"C Yang","year":"2025","unstructured":"Yang C, Sun C, Tan B, Hu C, Wan L, Wang C et al (2025) Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res 35:607\u2013609. https:\/\/doi.org\/10.1038\/s41422-025-01128-1","journal-title":"Cell Res"},{"key":"9151_CR57","doi-asserted-by":"publisher","unstructured":"Wang D, Wang X, Tan B, Wen X, Ye S, Wu Y et al (2025) Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med 100749. https:\/\/doi.org\/10.1016\/j.medj.2025.100749","DOI":"10.1016\/j.medj.2025.100749"},{"key":"9151_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D et al (2024) Anti\u2013CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med 391:376\u2013378. https:\/\/doi.org\/10.1056\/NEJMc2403743","journal-title":"N Engl J Med"},{"key":"9151_CR59","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/s0140-6736(24)02265-7","volume":"404","author":"M Hagen","year":"2024","unstructured":"Hagen M, M\u00fcller F, Wirsching A, Kharboutli S, Sp\u00f6rl S, Aigner M et al (2024) Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells. Lancet 404:2158\u20132160. https:\/\/doi.org\/10.1016\/s0140-6736(24)02265-7","journal-title":"Lancet"},{"key":"9151_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2128","author":"Z Hu","year":"2025","unstructured":"Hu Z, Cai S, Yu Y, Chen Y, Wang B, Wang D et al (2025) BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2128","journal-title":"Ann Rheum Dis"},{"key":"9151_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, Jin X, Cao H, Shao M et al (2025) Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03937-8","journal-title":"Nat Med"},{"key":"9151_CR62","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q et al (2021) Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Reviews Rep 17:2120\u20132123. https:\/\/doi.org\/10.1007\/s12015-021-10251-6","journal-title":"Stem Cell Reviews Rep"},{"key":"9151_CR63","doi-asserted-by":"publisher","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. . Ann Rheum Dis:ard-2024-225785 https:\/\/doi.org\/10.1136\/ard-2024-225785","DOI":"10.1136\/ard-2024-225785"},{"key":"9151_CR64","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.19723\/j.issn.1671-167X.2024.06.029","volume":"56","author":"M Wang","year":"2024","unstructured":"Wang M, Ding L, Wang M, Zou C, Yan S, Liang Y et al (2024) [Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy]. Beijing Da Xue Xue Bao Yi Xue Ban 56:1119\u20131125. https:\/\/doi.org\/10.19723\/j.issn.1671-167X.2024.06.029","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"9151_CR65","doi-asserted-by":"publisher","unstructured":"Sayed OA, Ellebedy M, Abu-Alsaud MA, Meligy AIB, Gheita TA (2025) CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies. . Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04425-z","DOI":"10.1007\/s00210-025-04425-z"},{"key":"9151_CR66","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A et al (2025) In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388:1311\u20131317. https:\/\/doi.org\/10.1126\/science.ads8473","journal-title":"Science"},{"key":"9151_CR67","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L et al (2025) In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. N Engl J Med 393:1542\u20131544. https:\/\/doi.org\/10.1056\/NEJMc2509522","journal-title":"N Engl J Med"},{"key":"9151_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03899-x","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S et al (2025) Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03899-x","journal-title":"Nat Med"},{"key":"9151_CR69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","volume":"144","author":"C Preu\u00dfe","year":"2022","unstructured":"Preu\u00dfe C, Paesler B, Nelke C, Cengiz D, M\u00fcntefering T, Roos A et al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 144:353\u2013372. https:\/\/doi.org\/10.1007\/s00401-022-02438-z","journal-title":"Acta Neuropathol"},{"key":"9151_CR70","doi-asserted-by":"publisher","unstructured":"Ruffer N, Krusche M, Stenzel W, Schneider U (2023) Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford) kead668. https:\/\/doi.org\/10.1093\/rheumatology\/kead668","DOI":"10.1093\/rheumatology\/kead668"},{"key":"9151_CR71","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S et al (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet (London England) 401:815\u2013818. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5","journal-title":"Lancet (London England)"},{"key":"9151_CR72","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, V\u00f6lkl S, Aigner M, Kleyer A et al (2024) Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford) 63:e12\u2013e4. https:\/\/doi.org\/10.1093\/rheumatology\/kead330","journal-title":"Rheumatology (Oxford)"},{"key":"9151_CR73","doi-asserted-by":"publisher","unstructured":"Taubmann J, Knitza J, M\u00fcller F, V\u00f6lkl S, Aigner M, Kretschmann S et al (2023) Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies: reply. Rheumatology (Oxford) kead669. https:\/\/doi.org\/10.1093\/rheumatology\/kead669","DOI":"10.1093\/rheumatology\/kead669"},{"key":"9151_CR74","doi-asserted-by":"publisher","unstructured":"Haase I, Richter J, Holzer M-T, Fehse B, Ruffer N, Seibel J et al (2025) A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy\u2014case report and literature review. . Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keaf190","DOI":"10.1093\/rheumatology\/keaf190"},{"key":"9151_CR75","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A-C Pecher","year":"2023","unstructured":"Pecher A-C, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA 329:2154\u20132162. https:\/\/doi.org\/10.1001\/jama.2023.8753","journal-title":"JAMA"},{"key":"9151_CR76","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, V\u00f6lkl S, Tur C, Raimondo MG et al (2025) BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med 31:1793\u20131797. https:\/\/doi.org\/10.1038\/s41591-025-03718-3","journal-title":"Nat Med"},{"key":"9151_CR77","doi-asserted-by":"publisher","first-page":"777502","DOI":"10.3389\/fimmu.2021.777502","volume":"12","author":"BB Cui","year":"2021","unstructured":"Cui BB, Tian YR, Ma XY, Yin G, Xie Q (2021) Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature. Front Immunol 12:777502. https:\/\/doi.org\/10.3389\/fimmu.2021.777502","journal-title":"Front Immunol"},{"key":"9151_CR78","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187:4890\u2013904e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"9151_CR79","doi-asserted-by":"publisher","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z et al (2024) Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial. Mol Ther:S1525001624005914 https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009","DOI":"10.1016\/j.ymthe.2024.09.009"},{"key":"9151_CR80","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.rdc.2021.07.003","volume":"47","author":"H Kim","year":"2021","unstructured":"Kim H, Huber AM, Kim S (2021) Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes. Rheum Dis Clin North Am 47:669\u2013690. https:\/\/doi.org\/10.1016\/j.rdc.2021.07.003","journal-title":"Rheum Dis Clin North Am"},{"key":"9151_CR81","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:740\u2013749. https:\/\/doi.org\/10.1002\/art.38270","journal-title":"Arthritis Rheumatol"},{"key":"9151_CR82","doi-asserted-by":"publisher","unstructured":"Nicolai R, Merli P, Moran Alvarez P, Bracaglia C, Del Bufalo F, Marasco E et al (2024) Autologous CD19- targeting CAR T cells in refractory juvenile dermatomyositis. Arthrit Rheumatol. (Hoboken, N.J.) https:\/\/doi.org\/10.1002\/art.42933","DOI":"10.1002\/art.42933"},{"key":"9151_CR83","doi-asserted-by":"publisher","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, Udaondo C, Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B et al (2025) CD19 CAR-T cell therapy in a pediatric patient with MDA5\u2009+\u2009dermatomyositis and rapidly progressive interstitial lung disease. Med 100676 https:\/\/doi.org\/10.1016\/j.medj.2025.100676","DOI":"10.1016\/j.medj.2025.100676"},{"key":"9151_CR84","doi-asserted-by":"publisher","unstructured":"Komura K (2024) CD19: a promising target for systemic sclerosis. Front Immunol Volume 15\u20132024. https:\/\/doi.org\/10.3389\/fimmu.2024.1454913","DOI":"10.3389\/fimmu.2024.1454913"},{"key":"9151_CR85","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3:e489\u2013e97. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7","journal-title":"Lancet Rheumatol"},{"key":"9151_CR86","doi-asserted-by":"publisher","unstructured":"Avouac J, Cauvet A, Orvain C, Boulch M, Tilotta F, Tu L et al (2023) Effects of B Cell Depletion by CD19-Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis. Arthr Rheumatol (Hoboken, N.J.) https:\/\/doi.org\/10.1002\/art.42677","DOI":"10.1002\/art.42677"},{"key":"9151_CR87","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, Gy\u00f6rfi A-H, V\u00f6lkl S, Aigner M et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82:1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"9151_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00282-0","author":"J Auth","year":"2024","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C et al (2024) CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/s2665-9913(24)00282-0","journal-title":"Lancet Rheumatol"},{"key":"9151_CR89","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","volume":"13","author":"W Merkt","year":"2025","unstructured":"Merkt W, R\u00f6hrich M, Mavriopoulou E, St\u00fctz AN, Distler JHW, Schmitt A et al (2025) Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years. Lancet Respiratory Med 13:651\u2013654. https:\/\/doi.org\/10.1016\/S2213-2600(25)00159-6","journal-title":"Lancet Respiratory Med"},{"key":"9151_CR90","doi-asserted-by":"publisher","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, R\u00f6hrich M et al (2023) Third-generation CD19.CAR-T cell-containing combination therapy in Scl70\u2009+\u2009systemic sclerosis. Ann Rheum Dis https:\/\/doi.org\/10.1136\/ard-2023-225174","DOI":"10.1136\/ard-2023-225174"},{"key":"9151_CR91","doi-asserted-by":"publisher","unstructured":"Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E et al (2025) Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keaf077","DOI":"10.1093\/rheumatology\/keaf077"},{"key":"9151_CR92","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","volume":"20","author":"C La Baldini","year":"2024","unstructured":"Baldini C, Fulvio G, La Rocca G, Ferro F (2024) Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 20:473\u2013491. https:\/\/doi.org\/10.1038\/s41584-024-01135-3","journal-title":"Nat Rev Rheumatol"},{"key":"9151_CR93","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman SJ, Everett CC, O\u2019Dwyer JL, Emery P, Pitzalis C, Ng WF et al (2017) Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren\u2019s Syndrome. Arthritis Rheumatol 69:1440\u20131450. https:\/\/doi.org\/10.1002\/art.40093","journal-title":"Arthritis Rheumatol"},{"key":"9151_CR94","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/m13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Pu\u00e9chal X et al (2014) Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med 160:233\u2013242. https:\/\/doi.org\/10.7326\/m13-1085","journal-title":"Ann Intern Med"},{"key":"9151_CR95","doi-asserted-by":"publisher","unstructured":"Ma JF, Xu T, Zhu HX, Chen XM, Li L, Zhao ZB et al (2025) Identification of Pathogenic PD-1(+)CD8(+) T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sj\u00f6gren Disease. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43144","DOI":"10.1002\/art.43144"},{"key":"9151_CR96","doi-asserted-by":"publisher","first-page":"1298815","DOI":"10.3389\/fimmu.2023.1298815","volume":"14","author":"L Sheng","year":"2023","unstructured":"Sheng L, Zhang Y, Song Q, Jiang X, Cao W, Li L et al (2023) Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol 14:1298815. https:\/\/doi.org\/10.3389\/fimmu.2023.1298815","journal-title":"Front Immunol"},{"key":"9151_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae714","author":"A Masihuddin","year":"2024","unstructured":"Masihuddin A, Liebowitz J, Reshef R, Bathon J (2024) Remission of lymphoma & rheumatoid arthritis following anti-CD19 chimeric antigen receptor T cell therapy for diffuse large B-cell lymphoma. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keae714","journal-title":"Rheumatology (Oxford)"},{"key":"9151_CR98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"9151_CR99","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-pathol-011811-132453","volume":"8","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Hu P, Xiao H (2013) Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 8:139\u2013160. https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132453","journal-title":"Annu Rev Pathol"},{"key":"9151_CR100","doi-asserted-by":"publisher","unstructured":"Lodka D, Zschummel M, Bunse M, Rousselle A, Sonnemann J, Kettritz R et al (2024) CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis:ard-2023-224875 https:\/\/doi.org\/10.1136\/ard-2023-224875","DOI":"10.1136\/ard-2023-224875"},{"key":"9151_CR101","doi-asserted-by":"publisher","first-page":"750753","DOI":"10.3389\/fimmu.2021.750753","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J et al (2021) B Cells in Rheumatoid Arthritis: Pathogenic Mechanisms and Treatment Prospects. Front Immunol 12:750753. https:\/\/doi.org\/10.3389\/fimmu.2021.750753","journal-title":"Front Immunol"},{"key":"9151_CR102","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2008.092791","volume":"68","author":"YK Teng","year":"2009","unstructured":"Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM (2009) Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68:1011\u20131016. https:\/\/doi.org\/10.1136\/ard.2008.092791","journal-title":"Ann Rheum Dis"},{"key":"9151_CR103","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, Sun J, Liu L, Huang D et al (2021) In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis 80:176\u2013184. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217844","journal-title":"Ann Rheum Dis"},{"key":"9151_CR104","doi-asserted-by":"publisher","unstructured":"A H, T H, D W, M B, V P, J M, et al (2024) Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2024-226017","DOI":"10.1136\/ard-2024-226017"},{"key":"9151_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226437","author":"M Lidar","year":"2024","unstructured":"Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O et al (2024) CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2024-226437","journal-title":"Ann Rheum Dis"},{"key":"9151_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-01068-2","author":"Y Li","year":"2025","unstructured":"Li Y, Li S, Zhao X, Sheng J, Xue L, Schett G et al (2025) Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. https:\/\/doi.org\/10.1038\/s41422-024-01068-2","journal-title":"Cell Res"},{"key":"9151_CR107","doi-asserted-by":"publisher","first-page":"m1067","DOI":"10.1136\/bmj.m1067","volume":"369","author":"M Lanzillotta","year":"2020","unstructured":"Lanzillotta M, Mancuso G, Della-Torre E (2020) Advances in the diagnosis and management of IgG4 related disease. BMJ 369:m1067. https:\/\/doi.org\/10.1136\/bmj.m1067","journal-title":"BMJ"},{"key":"9151_CR108","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","volume":"145","author":"E Della-Torre","year":"2020","unstructured":"Della-Torre E, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N et al (2020) B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease. J Allergy Clin Immunol 145:968\u201381e14. https:\/\/doi.org\/10.1016\/j.jaci.2019.07.004","journal-title":"J Allergy Clin Immunol"},{"key":"9151_CR109","doi-asserted-by":"publisher","first-page":"113779","DOI":"10.1016\/j.intimp.2024.113779","volume":"145","author":"Y Sun","year":"2025","unstructured":"Sun Y, Huang S, Zhang B, Peng Y, Lu H, Jia Y et al (2025) Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease. Int Immunopharmacol 145:113779. https:\/\/doi.org\/10.1016\/j.intimp.2024.113779","journal-title":"Int Immunopharmacol"},{"key":"9151_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.11.027","author":"V Keitel","year":"2025","unstructured":"Keitel V, Kreissl MC, Goetze T, Dr\u00f6ge C, Kuhn CK, Pham NN et al (2025) CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.11.027","journal-title":"J Hepatol"},{"key":"9151_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","volume":"6","author":"A Zufferey","year":"2017","unstructured":"Zufferey A, Kapur R, Semple JW (2017) Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med 6:16","journal-title":"J Clin Med"},{"key":"9151_CR112","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","volume":"405","author":"K Trautmann-Grill","year":"2025","unstructured":"Trautmann-Grill K, von Bonin M, Georgi A, Middeke JM, B\u00f6ttcher M, Meyer O et al (2025) Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells. Lancet 405:25\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(24)02504-2","journal-title":"Lancet"},{"key":"9151_CR113","doi-asserted-by":"publisher","first-page":"1228142","DOI":"10.3389\/fimmu.2023.1228142","volume":"14","author":"FVM Mulder","year":"2023","unstructured":"Mulder FVM, Evers D, de Haas M, Cruijsen MJ, Bernelot Moens SJ, Barcellini W et al (2023) Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps. Front Immunol 14:1228142. https:\/\/doi.org\/10.3389\/fimmu.2023.1228142","journal-title":"Front Immunol"},{"key":"9151_CR114","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/NEJMc2502297","volume":"392","author":"L Zhang","year":"2025","unstructured":"Zhang L, Gao Z, Pan H, Li R, Fang L, Li W et al (2025) BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy. N Engl J Med 392:2282\u20132284. https:\/\/doi.org\/10.1056\/NEJMc2502297","journal-title":"N Engl J Med"},{"key":"9151_CR115","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.coi.2025.102610","volume":"96","author":"PL Meroni","year":"2025","unstructured":"Meroni PL, Capobianco E, Tedesco F (2025) Can we cure antiphospholipid syndrome? Curr Opin Immunol 96:102610. https:\/\/doi.org\/10.1016\/j.coi.2025.102610","journal-title":"Curr Opin Immunol"},{"key":"9151_CR116","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/bjh.16266","volume":"188","author":"JL Schmelz","year":"2020","unstructured":"Schmelz JL, Navsaria L, Goswamy R, Chuang HH, Miranda RN, Lee HJ (2020) Chimeric antigen receptor T-cell therapy\u2019s role in antiphospholipid syndrome: a case report. Br J Haematol 188:e5\u2013e8. https:\/\/doi.org\/10.1111\/bjh.16266","journal-title":"Br J Haematol"},{"key":"9151_CR117","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","volume":"23","author":"E Friedberg","year":"2025","unstructured":"Friedberg E, Wohlfarth P, Schiefer AI, Skrabs C, Pickl WF, Worel N et al (2025) Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 23:262\u2013266. https:\/\/doi.org\/10.1016\/j.jtha.2024.09.024","journal-title":"J Thromb Haemost"},{"key":"9151_CR118","doi-asserted-by":"publisher","unstructured":"Liu X, Zhu W, Su N, Ma Y, Wang F, Xu J et al (2025) Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy. Front Immunol Volume 16\u20132025. https:\/\/doi.org\/10.3389\/fimmu.2025.1645304","DOI":"10.3389\/fimmu.2025.1645304"},{"key":"9151_CR119","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2013.278448","volume":"310","author":"R Jonsson","year":"2013","unstructured":"Jonsson R, Theander E, Sj\u00f6str\u00f6m B, Brokstad K, Henriksson G (2013) Autoantibodies present before symptom onset in primary Sj\u00f6gren syndrome. JAMA 310:1854\u20131855. https:\/\/doi.org\/10.1001\/jama.2013.278448","journal-title":"JAMA"},{"key":"9151_CR120","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/acr.23292","volume":"70","author":"N Leuchten","year":"2018","unstructured":"Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J et al (2018) Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care Res (Hoboken) 70:428\u2013438. https:\/\/doi.org\/10.1002\/acr.23292","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"9151_CR121","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10238-024-01357-5","volume":"24","author":"H Shao","year":"2024","unstructured":"Shao H, Wu Y, Tao X, Liu Q, Ran C, Jin L et al (2024) The titers of antinuclear antibodies are associated with the degree of inflammation and organ damage in Primary Sj\u00f6gren\u2019s Syndrome. Clin Exp Med 24:96. https:\/\/doi.org\/10.1007\/s10238-024-01357-5","journal-title":"Clin Exp Med"},{"key":"9151_CR122","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.36.2.157","volume":"36","author":"P Davis","year":"1977","unstructured":"Davis P, Percy JS, Russell AS (1977) Correlation between levels of DNA antibodies and clinical disease activity in SLE. Ann Rheum Dis 36:157\u2013159. https:\/\/doi.org\/10.1136\/ard.36.2.157","journal-title":"Ann Rheum Dis"},{"key":"9151_CR123","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/09612033241298729","volume":"33","author":"P Mor\u00e1n \u00c1lvarez","year":"2024","unstructured":"Mor\u00e1n \u00c1lvarez P, Bracaglia C, Nicolai R, Giovannelli L, Caiello I, Boni A et al (2024) Different patterns of longitudinal changes in antinuclear antibodies titers in children with systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome. Lupus 33:1594\u20131604. https:\/\/doi.org\/10.1177\/09612033241298729","journal-title":"Lupus"},{"key":"9151_CR124","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1038\/s41564-025-02115-3","volume":"10","author":"X Zhang","year":"2025","unstructured":"Zhang X, Li Y, Qin Y, Liao Z, Deng C, Chen Y et al (2025) Vientovirus capsid protein mimics autoantigens and contributes to autoimmunity in Sj\u00f6gren\u2019s disease. Nat Microbiol 10:2591\u20132602. https:\/\/doi.org\/10.1038\/s41564-025-02115-3","journal-title":"Nat Microbiol"},{"key":"9151_CR125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-023-00982-8","volume":"30","author":"C Yang","year":"2023","unstructured":"Yang C, Nguyen J, Yen Y (2023) Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. J Biomed Sci 30:89. https:\/\/doi.org\/10.1186\/s12929-023-00982-8","journal-title":"J Biomed Sci"},{"key":"9151_CR126","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.Ccr-10-1198","volume":"17","author":"I Tawara","year":"2011","unstructured":"Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R et al (2011) Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clin Cancer Res 17:77\u201388. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-1198","journal-title":"Clin Cancer Res"},{"key":"9151_CR127","doi-asserted-by":"publisher","first-page":"129","DOI":"10.20892\/j.issn.2095-3941.2022.0585","volume":"20","author":"P Li","year":"2023","unstructured":"Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y et al (2023) 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biol Med 20:129\u2013146. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0585","journal-title":"Cancer Biol Med"},{"key":"9151_CR128","doi-asserted-by":"publisher","unstructured":"Umair MM, Lai X, Xue Y, Yao H (2025) Influence of CAR T-cell therapy associated complications. Front Oncol Volume 15\u20132025. https:\/\/doi.org\/10.3389\/fonc.2025.1494986","DOI":"10.3389\/fonc.2025.1494986"},{"key":"9151_CR129","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","volume":"45","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N, Jain M, Sharma K, Jain S et al (2025) Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int 45:18. https:\/\/doi.org\/10.1007\/s00296-024-05772-5","journal-title":"Rheumatol Int"},{"key":"9151_CR130","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41409-023-02086-1","volume":"58","author":"J Wang","year":"2023","unstructured":"Wang J, Alkrekshi A, Dasari S, Lin H-TC, Elantably D, Armashi ARA (2023) CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. Bone Marrow Transpl 58:1223\u20131228. https:\/\/doi.org\/10.1038\/s41409-023-02086-1","journal-title":"Bone Marrow Transpl"},{"key":"9151_CR131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028375","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A et al (2025) Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood.2025028375","journal-title":"Blood"},{"key":"9151_CR132","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41591-023-02716-7","volume":"30","author":"C Arnold","year":"2024","unstructured":"Arnold C (2024) Autoimmune disease is the next frontier for CAR T cell therapy. Nat Med 30:6\u20139. https:\/\/doi.org\/10.1038\/s41591-023-02716-7","journal-title":"Nat Med"},{"key":"9151_CR133","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe G, Br\u00fcggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S et al (2024) Aggressive Lymphoma after CD19 CAR T-Cell Therapy. N Engl J Med 391:1217\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa2402730","journal-title":"N Engl J Med"},{"key":"9151_CR134","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3324\/haematol.2024.286021","volume":"110","author":"AP Boardman","year":"2025","unstructured":"Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA et al (2025) Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy. Haematologica 110:651\u2013664. https:\/\/doi.org\/10.3324\/haematol.2024.286021","journal-title":"Haematologica"},{"key":"9151_CR135","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jtct.2025.03.007","volume":"31","author":"K Sadowski","year":"2025","unstructured":"Sadowski K, Ploch W, Downar A, Giza W, Szcze\u015b D, Olejarz W et al (2025) Nephrotoxicity in CAR-T Cell Therapy. Transplant Cell Ther 31:407\u2013418. https:\/\/doi.org\/10.1016\/j.jtct.2025.03.007","journal-title":"Transplantation Cell Therapy"},{"key":"9151_CR136","doi-asserted-by":"publisher","first-page":"152610","DOI":"10.1016\/j.semarthrit.2024.152610","volume":"71","author":"JA G\u00f3mez-Puerta","year":"2025","unstructured":"G\u00f3mez-Puerta JA, Monegal A, Ponce A, Peris P, Mart\u00ednez-Cibrian N, Sarmiento-Monroy JC et al (2025) Rheumatologic complications of CAR-T Cell therapy. Experience of a single center. Semin Arthritis Rheum 71:152610. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152610","journal-title":"Semin Arthritis Rheum"},{"key":"9151_CR137","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/s2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, M\u00fcller F, Wirsching A, Kharboutli S, Spoerl S, D\u00fcsing C et al (2025) Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol 7:e424\u2013e33. https:\/\/doi.org\/10.1016\/s2665-9913(25)00091-8","journal-title":"Lancet Rheumatol"},{"key":"9151_CR138","doi-asserted-by":"publisher","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X (2022) Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol 10:1034257. https:\/\/doi.org\/10.3389\/fcell.2022.1034257","journal-title":"Front Cell Dev Biol"},{"key":"9151_CR139","doi-asserted-by":"publisher","unstructured":"Yin F, He Y, Li J, Gao Y (2025) Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting. Front Immunol Volume 16\u20132025. https:\/\/doi.org\/10.3389\/fimmu.2025.1596686","DOI":"10.3389\/fimmu.2025.1596686"},{"key":"9151_CR140","doi-asserted-by":"publisher","unstructured":"Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J et al (2025) Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients. Int J Mol Sci 26. https:\/\/doi.org\/10.3390\/ijms26020467","DOI":"10.3390\/ijms26020467"},{"key":"9151_CR141","doi-asserted-by":"publisher","first-page":"1561174","DOI":"10.3389\/fimmu.2025.1561174","volume":"16","author":"K Rassek","year":"2025","unstructured":"Rassek K, Misiak J, O\u0142dak T, Rozwadowska N, Basak G, Kolanowski T (2025) New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies. Front Immunol 16:1561174. https:\/\/doi.org\/10.3389\/fimmu.2025.1561174","journal-title":"Front Immunol"},{"key":"9151_CR142","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.beha.2024.101595","volume":"37","author":"J Wang","year":"2024","unstructured":"Wang J, Caimi PF (2024) CAR assembly line: Taking CAR T-cell manufacturing to the next level. Best Pract Res Clin Haematol 37:101595. https:\/\/doi.org\/10.1016\/j.beha.2024.101595","journal-title":"Best Pract Res Clin Haematol"},{"key":"9151_CR143","doi-asserted-by":"publisher","first-page":"e397912","DOI":"10.1200\/edbk_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, Kelkar AH, Russler-Germain DA, Tessema FA, Raymakers AJN, Feldman WB et al (2023) High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. Am Soc Clin Oncol Educ Book 43:e397912. https:\/\/doi.org\/10.1200\/edbk_397912","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9151_CR144","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","volume":"27","author":"K Thavorn","year":"2024","unstructured":"Thavorn K, Thompson ER, Kumar S, Heiskanen A, Agarwal A, Atkins H et al (2024) Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. Value Health 27:1149\u20131173. https:\/\/doi.org\/10.1016\/j.jval.2024.04.004","journal-title":"Value Health"},{"key":"9151_CR145","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, Mackensen A, Wang W, Furie RA et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20:531\u2013544. https:\/\/doi.org\/10.1038\/s41584-024-01139-z","journal-title":"Nat Rev Rheumatol"},{"key":"9151_CR146","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","volume":"31","author":"SS Raj","year":"2025","unstructured":"Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA et al (2025) An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med 31:1183\u20131194. https:\/\/doi.org\/10.1038\/s41591-025-03532-x","journal-title":"Nat Med"},{"key":"9151_CR147","doi-asserted-by":"publisher","first-page":"790e1","DOI":"10.1016\/j.jtct.2024.05.025","volume":"30","author":"J Khouri","year":"2024","unstructured":"Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L et al (2024) Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transpl Cell Ther 30:790e1\u2013e16. https:\/\/doi.org\/10.1016\/j.jtct.2024.05.025","journal-title":"Transpl Cell Ther"},{"key":"9151_CR148","doi-asserted-by":"publisher","first-page":"118e1","DOI":"10.1016\/j.jtct.2021.11.016","volume":"28","author":"Y Liu","year":"2022","unstructured":"Liu Y, Chen W, Yu M, Li H, Cheng H, Cao J et al (2022) Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells. Transpl Cell Ther 28:118e1\u2013e5. https:\/\/doi.org\/10.1016\/j.jtct.2021.11.016","journal-title":"Transpl Cell Ther"},{"key":"9151_CR149","doi-asserted-by":"publisher","first-page":"18696","DOI":"10.1038\/s41598-022-23589-9","volume":"12","author":"F Wada","year":"2022","unstructured":"Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J et al (2022) T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. Sci Rep 12:18696. https:\/\/doi.org\/10.1038\/s41598-022-23589-9","journal-title":"Sci Rep"},{"key":"9151_CR150","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.ard.2025.03.018","volume":"84","author":"AC Pecher","year":"2025","unstructured":"Pecher AC, Hensen L, Schairer-Marquardt R, Kowarik M, Richter V, Bethge W et al (2025) Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation. Ann Rheum Dis 84:1284\u20131286. https:\/\/doi.org\/10.1016\/j.ard.2025.03.018","journal-title":"Ann Rheum Dis"},{"key":"9151_CR151","doi-asserted-by":"publisher","first-page":"5845167","DOI":"10.1155\/jimr\/5845167","volume":"2025","author":"C Zhang","year":"2025","unstructured":"Zhang C, Liu H (2025) Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies. J Immunol Res 2025:5845167. https:\/\/doi.org\/10.1155\/jimr\/5845167","journal-title":"J Immunol Res"},{"key":"9151_CR152","doi-asserted-by":"publisher","unstructured":"Nolan-Stevaux O, Smith R (2024) Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol Volume 15\u20132024. https:\/\/doi.org\/10.3389\/fimmu.2024.1490911","DOI":"10.3389\/fimmu.2024.1490911"},{"key":"9151_CR153","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L et al (2024) Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med 390:1290\u20131298. https:\/\/doi.org\/10.1056\/NEJMoa2314390","journal-title":"N Engl J Med"},{"key":"9151_CR154","doi-asserted-by":"publisher","first-page":"eadz0529","DOI":"10.1126\/scitranslmed.adz0529","volume":"17","author":"X Liu","year":"2025","unstructured":"Liu X, Zhang J, Chu J, Chen YJ, Qian C, Wang HY et al (2025) ZAP327 signaling domain-driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models. Sci Transl Med 17:eadz0529. https:\/\/doi.org\/10.1126\/scitranslmed.adz0529","journal-title":"Sci Transl Med"},{"key":"9151_CR155","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-024-01648-0","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q et al (2024) Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. J Hematol Oncol 17:122. https:\/\/doi.org\/10.1186\/s13045-024-01648-0","journal-title":"J Hematol Oncol"},{"key":"9151_CR156","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/hgtb.2012.050","volume":"23","author":"V Marin","year":"2012","unstructured":"Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A et al (2012) Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells. Hum Gene Therapy Methods 23:376\u2013386. https:\/\/doi.org\/10.1089\/hgtb.2012.050","journal-title":"Hum Gene Therapy Methods"},{"key":"9151_CR157","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247\u20134254. https:\/\/doi.org\/10.1182\/blood-2004-11-4564","journal-title":"Blood"},{"key":"9151_CR158","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jcyt.2024.11.013","volume":"27","author":"R Traynor","year":"2025","unstructured":"Traynor R, Vignola I, Sarkar S, Prochazkova M, Cai Y, Shi R et al (2025) Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy. Cytotherapy 27:400\u2013409. https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.013","journal-title":"Cytotherapy"},{"key":"9151_CR159","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.7150\/thno.101941","volume":"14","author":"R Lv","year":"2024","unstructured":"Lv R, Guo Y, Liu W, Dong G, Liu X, Li C et al (2024) Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy. Theranostics 14:7424\u20137447. https:\/\/doi.org\/10.7150\/thno.101941","journal-title":"Theranostics"},{"key":"9151_CR160","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini L, Bl\u00f6mer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263\u2013267. https:\/\/doi.org\/10.1126\/science.272.5259.263","journal-title":"Science"},{"key":"9151_CR161","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","volume":"12","author":"M Themis","year":"2005","unstructured":"Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F et al (2005) Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12:763\u2013771. https:\/\/doi.org\/10.1016\/j.ymthe.2005.07.358","journal-title":"Mol Ther"},{"key":"9151_CR162","doi-asserted-by":"publisher","unstructured":"(2024) In Vivo CAR Monocytes Show Efficacy in Mice. Cancer Discov 14:10. https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2023-0083","DOI":"10.1158\/2159-8290.Cd-nb2023-0083"},{"key":"9151_CR163","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","volume":"8","author":"Z Ye","year":"2022","unstructured":"Ye Z, Chen J, Zhao X, Li Y, Harmon J, Huang C et al (2022) In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery. ACS Biomater Sci Eng 8:722\u2013733. https:\/\/doi.org\/10.1021\/acsbiomaterials.1c01532","journal-title":"ACS Biomater Sci Eng"},{"key":"9151_CR164","doi-asserted-by":"publisher","first-page":"e2310078","DOI":"10.1002\/adma.202310078","volume":"36","author":"C Zhu","year":"2024","unstructured":"Zhu C, Ke L, Ao X, Chen Y, Cheng H, Xin H et al (2024) Injectable Supramolecular Hydrogels for In Situ Programming of Car-T Cells toward Solid Tumor Immunotherapy. Adv Mater 36:e2310078. https:\/\/doi.org\/10.1002\/adma.202310078","journal-title":"Adv Mater"},{"key":"9151_CR165","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D et al (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol 12:813\u2013820. https:\/\/doi.org\/10.1038\/nnano.2017.57","journal-title":"Nat Nanotechnol"},{"key":"9151_CR166","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2024.04.040","volume":"370","author":"VV Inamdar","year":"2024","unstructured":"Inamdar VV, Hao S, Stephan SB, Stephan MT (2024) Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes. J Control Release 370:310\u2013317. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.040","journal-title":"J Control Release"},{"key":"9151_CR167","doi-asserted-by":"publisher","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin H, Cheng J, Mu W, Zhou J, Zhu L (2021) Advances in Universal CAR-T Cell Therapy. Front Immunol 12:744823. https:\/\/doi.org\/10.3389\/fimmu.2021.744823","journal-title":"Front Immunol"},{"key":"9151_CR168","doi-asserted-by":"publisher","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E et al (2024) Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biology 12\u20132024. https:\/\/doi.org\/10.3389\/fcell.2024.1491282","DOI":"10.3389\/fcell.2024.1491282"},{"key":"9151_CR169","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW (2018) Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell 173:1426. https:\/\/doi.org\/10.1016\/j.cell.2018.03.038. 38.e11","journal-title":"Cell"},{"key":"9151_CR170","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C et al (2024) Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med 30:1593\u20131601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1","journal-title":"Nat Med"},{"key":"9151_CR171","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S, N\u00f6thling DM, Rothe T, Anoshkin K et al (2024) BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease. N Engl J Med 391:867\u2013869. https:\/\/doi.org\/10.1056\/NEJMc2408786","journal-title":"N Engl J Med"},{"key":"9151_CR172","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, Camisa B, Toma C, Norata R et al (2024) Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat Commun 15:2542. https:\/\/doi.org\/10.1038\/s41467-024-46448-9","journal-title":"Nat Commun"},{"key":"9151_CR173","first-page":"L17","volume":"2024","author":"Y Yu","year":"2024","unstructured":"Yu Y, Kong R, Xu X, Liu S, Chen Q, Li X et al (2024) Allogenic CD19 CAR NK cells therapy in refractory systemic lupus erythematosus: an open-label, single arm, prospective and interventional clinical trial. ACR Convergence. 2024:L17","journal-title":"ACR Convergence"},{"key":"9151_CR174","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J et al (2025) An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell 188:4225\u20134238. https:\/\/doi.org\/10.1016\/j.cell.2025.05.038. .e12","journal-title":"Cell"},{"key":"9151_CR175","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Sci (New York N Y) 353:179\u2013184. https:\/\/doi.org\/10.1126\/science.aaf6756","journal-title":"Sci (New York N Y)"},{"key":"9151_CR176","doi-asserted-by":"publisher","first-page":"eadt0795","DOI":"10.1126\/sciadv.adt0795","volume":"11","author":"S Oh","year":"2025","unstructured":"Oh S, Khani-Habibabadi F, O\u2019Connor KC, Payne AS (2025) Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Sci Adv 11:eadt0795. https:\/\/doi.org\/10.1126\/sciadv.adt0795","journal-title":"Sci Adv"},{"key":"9151_CR177","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0140-6736(24)01267-4","volume":"404","author":"E Gremese","year":"2024","unstructured":"Gremese E, Bruno D, Ferraccioli G (2024) CAR T-cell perspectives in lupus. Lancet 404:336. https:\/\/doi.org\/10.1016\/S0140-6736(24)01267-4","journal-title":"Lancet"},{"key":"9151_CR178","doi-asserted-by":"publisher","first-page":"e70146","DOI":"10.1111\/cts.70146","volume":"18","author":"H Park","year":"2025","unstructured":"Park H, Mugundu GM, Singh AP (2025) Mechanistic Evaluation of Anti-CD19 CAR-T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model. Clin Transl Sci 18:e70146. https:\/\/doi.org\/10.1111\/cts.70146","journal-title":"Clin Transl Sci"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09151-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:25:04Z","timestamp":1776684304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9151"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09151-9","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the authors used ChatGPT for AI assisted copy editing. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI in Scientific Writing"}},{"value":"The authors used Microsoft\u00ae PowerPoint\u00ae 2021MSO to prepare figures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Preparing Figures"}}],"article-number":"35"}}